UroGen Pharma (URGN)
Develops localized mitomycin therapies for low-grade urothelial cancers.
Something off on this page? Send us feedback.
Commercializes JELMYTO and ZUSDURI, RTGel-based mitomycin products for selected low-grade urothelial cancers, primarily in the United States. The single-segment business depends on specialist adoption, distributor-based product sales, FDA-regulated indications, and follow-on RTGel programs.
Uses RTGel, a reverse-thermal hydrogel, to keep mitomycin in local contact with urothelial tumors. Marketed products include JELMYTO for low-grade upper tract urothelial cancer and ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Operates as one reportable segment with product sales primarily in the United States through national specialty distributors. The model is small and focused, built around physician adoption in urology and moving procedure-heavy treatment settings toward localized drug therapy.
Execution depends on FDA-approved indications, reimbursement, specialty-distributor access, commercialization of JELMYTO and ZUSDURI, and follow-on RTGel programs. JELMYTO also carries a future generic-license path under the Teva settlement if a generic version receives FDA approval.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Jefferies | Reiterate | Rating: —Target: $40 | Target: $56 |
| Aug 6, 2026 | Guggenheim | Reiterate | Rating: —Target: $42 | Target: $58 |
| Aug 6, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $45 | Target: $75 |
| Jul 21, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $42 |
| Jul 16, 2026 | Oppenheimer | Reiterate | Rating: —Target: $31 | Target: $50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $108.0M · Total debt $196.1M · Total assets $252.6M · Shareholders' equity −$132.4M
- Revenue
- $72.5M
- Operating income
- $111.0K
- Net income
- −$14.4M
No dividends on record.
| Institutions | 87.06% | 42.56M shares | |
|---|---|---|---|
| 199 holders · as of Jun 30, 2026 | |||
| Insiders | 0.27% | 131.3K shares | |
| 8 holders · as of Sep 9, 2026 | |||
| Other | 12.67% | 6.19M shares | |
| remainder | |||
48.88M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RTW Investments, LPInstitution | 9.30% | 4.54M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.55% | 3.20M | as of Jun 30, 2026 |
The Toronto-Dominion BankInstitution | 5.35% | 2.62M | filed May 15, 2026 |
Morgan StanleyInstitution | 5.27% | 2.58M | as of Jun 30, 2026 |
Kynam Capital Management, LPInstitution | 4.98% | 2.43M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Jason Drew Smith | officer: General Counsel | −1,519 | $42.54 |
| Sep 8, 2026 | Mark Schoenberg | officer: Chief Medical Officer | −871 | $42.92 |
| Aug 20, 2026 | Mark Schoenberg | officer: Chief Medical Officer | −60,677 | $47.05 |
| Jul 9, 2026 | Mark Schoenberg | officer: Chief Medical Officer | −10,000 | $40.00 |
| Jun 22, 2026 | Mark Schoenberg | officer: Chief Medical Officer | −10,000 | $35.01 |
- Tyra Biosciences
Oral FGFR3 program in low-grade IR NMIBC and LG-UTUC
- CG Oncology
Bladder-sparing cretostimogene program across NMIBC
- Johnson & Johnson
Approved extended-release intravesical gemcitabine for high-risk NMIBC
- ImmunityBio
Commercial ANKTIVA plus BCG franchise in BCG-unresponsive NMIBC
- Merck
KEYTRUDA immunotherapy option in high-risk NMIBC
- Teva (ADR)
Licensed future generic JELMYTO path after 2030
- enGene Therapeutics
Intravesical gene therapy for BCG-unresponsive high-risk NMIBC
- Protara Therapeutics
Cell-based immunotherapy program for high-grade NMIBC
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| UroGen Pharma | $43.10 | −0.22% | $2.10B | — | 35.0 | 11.2 | +199.2% |
| Tyra Biosciences | $25.72 | +0.27% | $1.53B | — | — | — | — |
| CG Oncology | $78.32 | +0.09% | $6.90B | — | — | 1,108.2 | — |
| Johnson & Johnson | $267.28 | −0.81% | $649.40B | 31.2 | 22.5 | 6.6 | +6.6% |
| ImmunityBio | $8.80 | +4.08% | $8.85B | — | — | 53.4 | +93.9% |
| Merck | $151.04 | +1.03% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Teva (ADR) | $39.80 | −0.65% | $46.66B | 66.8 | 14.2 | 2.7 | −0.8% |
| enGene Therapeutics | $2.01 | +2.30% | $131.3M | — | — | — | — |
| Protara Therapeutics | $3.79 | +7.98% | $197.3M | — | — | — | — |
| Median | 66.8 | 17.5 | 6.6 | +5.8% |